Introduction {#s1}
============

Immune checkpoint inhibitors (ICIs) represent an emerging class of anticancer therapy, which has modified the outcome of several metastatic solid tumours, as well as locally advanced melanoma and non-small cell lung cancer. ICIs are antagonist antibodies that target immune checkpoints located either on T-cells, such as PD-1 and cytotoxic T-lymphocyte antigen-4, or on neoplastic cells, such as PD-1 ligand. These checkpoints are physiologically important for immune homeostasis and activated by cancer cells to evade immune system destruction \[[@C1]\]. ICIs interfere with this process, and reactivate the priming and effector phases of the immune response against the neoplastic cells, which has been shown to result in a systemic, complete and durable cancer response in a subset of patients. Recently, a synergistic effect of immunotherapy and radiotherapy (RT) has been suggested in selected patients, with several studies demonstrating a significant prolonged progression-free survival and overall survival when immunotherapy is combined with previous or concomitant RT \[[@C2]--[@C9]\].

Although ICIs have an overall safe profile, alone or in combination with RT, specific complications called immune-related adverse events (irAEs) may occur in up to 85% of patients \[[@C10]\]. Fortunately, most of them are manageable grade 1 or 2 events. Among them, immune-related pneumonitis (IP) is rare, occurring in around 2--5% of patients (1% grade 3--5), but is relevant because it may lead to respiratory failure \[[@C11]\]. IP generally responds to immunotherapy interruption and steroids or immunosuppressive drugs, but it requires a prompt and correct identification \[[@C10]\], and may impact the subsequent therapeutic management.

An early and accurate diagnosis of IP may be challenging since the clinical and imaging features are not specific. Several imaging patterns have been reported such as organising pneumonia, nonspecific interstitial pneumonia (NSIP), hypersensitivity pneumonitis, acute interstitial pneumonitis/diffuse alveolar damage syndrome (DAD) and in some cases, no specific appearance (not otherwise specified pneumonia) \[[@C12], [@C13]\]. Moreover, neither specific triggers nor underlying clinical or pathological lung conditions have been correlated with IP occurrence. Recently, the development of IP in previously irradiated areas of the lung has been reported in a few cases, suggesting a "hyperactivation" of T-cells in the RT field or a "radiation recall" effect \[[@C14]--[@C16]\]. However, to date, insufficient data are available to confirm this hypothesis. The aim of this retrospective study was to evaluate the relationships between IP and underlying lung conditions, especially tumour location and previous RT.

Materials and methods {#s2}
=====================

Patients {#s2a}
--------

This retrospective observational study was performed after obtaining institutional research informed consent from all patients, allowing anonymous data analysis. All patients with a suspicion of IP discussed in our multidisciplinary board were reviewed in this retrospective case series. All patients received ICIs for a neoplastic disease within clinical trials or according to routine care (RC) at our institution. All biological and radiological examinations were performed according to RC.

Inclusion criteria were the following: 1) New onset of a clinical or radiological event suspicious for IP during ICI treatment: terminology and severity of the adverse event were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2) Chest computed tomography (CT) scan. 3) Bronchoalveolar lavage (BAL) or biopsy performed at the time of IP. When BAL or biopsy were not performed because of IP severity, improvement after ICI interruption and steroids was considered as a diagnostic confirmation of IP. Cases with sarcoidosis-like irAEs or lung infection were excluded.

Imaging assessment {#s2b}
------------------

Three independent readers retrospectively reviewed the chest CT scans: two experienced thoracic oncology radiologists (C. Pozzessere and C. Beigelman-Aubry) and one respiratory physician specialised in interstitial lung diseases (R. Lazor). The readers analysed imaging acquired at the following time points: before immunotherapy, before the onset of IP, and at IP diagnosis. For the purpose of this analysis, the last CT scan before appearance of IP was considered as a "baseline scan" and the one at the time of IP diagnosis as the "IP scan". In patients who underwent RT, CT scans before and after RT were also assessed, and the presence or absence of RT-induced pneumonia was recorded. Pre-existing radiation-induced abnormalities were not considered as immune-related in the assessment of IP features.

Each lung was divided into three regions: the upper lung from the apex to the carina, the middle lung from the carina to the lower pulmonary veins and the lower lung from the lower pulmonary veins to the diaphragm, making a total of six lung regions per patient. The specific pulmonary findings and their distribution were assessed according to the Fleischner Society terminology \[[@C17]\] and the extent of involvement for each region was determined on a five-point Likert scale (0%, 1--25%, 26--50%, 51--75% and 76%--100%). Then, an imaging pattern was attributed according to the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of idiopathic interstitial pneumonias \[[@C18]\].

For patients who received RT, all treatments were delivered with intensity modulated RT techniques using helical tomotherapy or volumetric modulated arc therapy. RT plans were coregistered with the baseline scan and the IP scan to evaluate whether IP-related lesions were within the RT field. In addition, the percentage of IP within and outside the RT field was visually assessed, ranging from 100% when the involvement was entirely confined within the RT field to 0% when no abnormalities were detected in the RT field. A 5-Gy isodose line was chosen to determine the edge of RT fields.

CT studies after ICI interruption and steroids administration were also reviewed to assess the resolution of IP abnormalities.

Cytological and histological analysis {#s2c}
-------------------------------------

Cytological and histological specimens were analysed by two lung pathologists. The BAL differential cell count was used in combination with imaging to classify each case into clinical patterns according to the ATS/ERS guidelines \[[@C18]\]. Infection was ruled out by BAL microbiology analysis and/or clinical course.

Statistical analysis {#s2d}
--------------------

The Fischer\'s exact test was used to evaluate the prevalence of IP in lung regions with or without previous tumour, metastasis or RT, and the differences in CT pattern between RT-treated and RT-naïve patients. The proportion of lung parenchyma infiltration by IP was measured on CT and dichotomised using a threshold ≥1% *versus* 0%. The probability of IP by lung regions was analysed by logistic regression according to the presence or absence of previous tumour, metastasis or RT. Statistical analyses were conducted on Stata 15.1 (StataCorp, College Station, TX, USA) with p\<0.05 as significance level.

Results {#s3}
=======

Among 253 cancer patients treated with ICIs at our institution, 15 patients (10 males; median age 68 years, range 48--88 years) presenting with symptoms of IP according to CTCAE version 4.0 criteria (n=9) or compatible radiological findings (n=6) were retrospectively included. Four of them were included in clinical trials and 11 treated according to RC. Eight other patients were excluded because of sarcoid-like reactions (n=5) or lung infection (n=3). The diagnosis of IP was confirmed by BAL (n=11) and/or tissue sampling (n=2). In two patients, recovery after immunotherapy interruption and steroid administration was considered as a diagnostic confirmation of IP.

Nine patients had lung cancer (61%), four had melanoma (27%), one had a parotid epidermoid carcinoma (6%) and one had oesophageal cancer (6%). Six patients (40%) were treated with nivolumab, two (13%) with ipilimumab, four (27%) with combined ipilimumab and nivolumab (followed by nivolumab maintenance therapy in three), one (6%) with durvalumab and tremelimumab, and two (13%) with pembrolizumab. Patient characteristics are shown in [tables 1](#TB1){ref-type="table"} and [2](#TB2){ref-type="table"}.

###### 

Patient characteristics

  **Case number**   **Age years**   **Sex**   **Time of diagnosis**   **Tumour histology**                                                                                           **Stage**   **Intrathoracic tumour manifestations at diagnosis**                                                                                                            **Chemotherapy**                                                         **RT**   **Intrathoracic tumour manifestations before RT**                                                                                                               **Time of RT**           **Events other than RT in the 18 months before the onset of IP**          **Intrathoracic tumour manifestations before ICI**
  ----------------- --------------- --------- ----------------------- -------------------------------------------------------------------------------------------------------------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  **1**             88              M         May 2014                Metastatic squamous cell carcinoma of the head and neck                                                        IV          Bilateral lung metastasis, right hilar metastasis                                                                                                               NA                                                                       Yes      Bilateral lung metastasis, right hilar metastasis                                                                                                               Dec 2014 to Feb 2016     *Pseudomonas aeruginosa* pneumonia                                        Bilateral lung metastasis, right hilar metastasis
  **2**             70              M         Jan 2013                1\) Mixed small cell carcinoma and squamous cell carcinoma of the lung2) Squamous cell carcinoma of the lung   IIB         Primary carcinoma (mass) LUL (1), synchronous primary carcinoma RUL (2), left-sided metastatic mediastinal and hilar lymph nodes, small left pleural effusion   Cisplatin/etoposide                                                      Yes      Primary carcinoma (mass) LUL (1), synchronous primary carcinoma RUL (2), left-sided metastatic mediastinal and hilar lymph nodes, small left pleural effusion   Jan to July 2013         Lung metastasis cryoablation                                              LLL metastasis extending to the chest wall
  **3**             69              M         May 2016                Squamous cell carcinoma of the lung                                                                            IV          Primary carcinoma of the RUL, homolateral LN metastasis, thoracic spine metastasis T7--T11                                                                      No                                                                       Yes      Primary carcinoma of the RUL, homolateral LN metastasis, thoracic spine metastasis T7--T11                                                                      June 2016 (spine)        No                                                                        Primary carcinoma of the RUL, homolateral LN metastasis, thoracic spine metastasis T7--T11
  **4**             58              M         Jan 2010                Melanoma                                                                                                       IB          None                                                                                                                                                            No                                                                       Yes      Lung metastasis RLL (after incomplete surgical resection)                                                                                                       July 2015                Community-acquired pneumonia                                              New nodule RUL
  **5**             68              F         June 2015               Melanoma                                                                                                       IIIB        Nonhypermetabolic nodule LLL, chest wall metastasis                                                                                                             No                                                                       No       NA                                                                                                                                                              No                       Rhinovirus bronchiolitis, recurrence of chest wall and liver metastasis   Chest wall metastasis
  **6**             80              M         June 2016               Squamous cell carcinoma of the lung                                                                            IV          Primary carcinoma LLL, previous left upper lobectomy in 2014 for adenocarcinoma of the LUL                                                                      Carboplatin/vinorelbine (first carcinoma) then carboplatin/gemcitabine   No       NA                                                                                                                                                              No                       Drug-induced thrombopenia                                                 Primary carcinoma LLL, previous left upper lobectomy
  **7**             75              M         March 2016              Lung adenocarcinoma                                                                                            IV          Primary carcinoma LUL                                                                                                                                           No                                                                       No       NA                                                                                                                                                              No                       No                                                                        Primary carcinoma LUL
  **8**             59              F         July 2015               Squamous cell carcinoma of the lung                                                                            IV          Primary carcinoma (mass) RUL                                                                                                                                    Cisplatin/vinorelbine then carboplatin/vinorelbine                       Yes      Surgical resection of RUL                                                                                                                                       Jan to Feb 2016          *Pneumocystis jiroveci* pneumonia                                         Local recurrence LLL metastasis
  **9**             51              F         Jan 2014                Small cell lung cancer                                                                                         IB          Primary carcinoma (mass) RLL                                                                                                                                    Cisplatin/etoposide                                                      Yes      Primary carcinoma (mass) RLL                                                                                                                                    Feb 2015 to March 2016   No                                                                        Primary carcinoma (mass) RLL
  **10**            57              F         Feb 2015                Lung adenocarcinoma                                                                                            IV          Primary carcinoma (mass) LUL                                                                                                                                    Pemetrexed then carboplatin/pemetrexed                                   Yes      Primary carcinoma (mass) LUL                                                                                                                                    Sept to Oct 2015         No                                                                        Primary carcinoma (mass) LUL
  **11**            48              M         March 2007              Right arm melanoma                                                                                             IB          No                                                                                                                                                              No                                                                       No       NA                                                                                                                                                              No                       No                                                                        Melanoma metastasis (mass) RUL
  **12**            71              M         Feb 2017                Oesophageal adenocarcinoma                                                                                     IV          Oesophageal carcinoma, locoregional metastatic lymph nodes                                                                                                      No                                                                       Yes      Chest wall metastasis                                                                                                                                           March 2017               No                                                                        Chest wall metastasis
  **13**            88              M         Oct 2015                Squamous cell carcinoma of the lung                                                                            IIIA        Primary carcinoma of RUL extending to chest wall, mediastinal and right hilar lymph node metastasis                                                             Gemcitabine                                                              Yes      Primary carcinoma of RUL extending to chest wall, mediastinal and right hilar lymph node metastasis                                                             Nov 2015 to Feb 2016     No                                                                        Primary carcinoma of RUL extending to chest wall, mediastinal and right hilar lymph node metastasis
  **14**            62              M         Feb 2007                Melanoma                                                                                                       IV          Mediastinal and hilar metastasis and metastasis of the RLL                                                                                                      Dacarbazine                                                              No       NA                                                                                                                                                              No                       No                                                                        Mediastinal and hilar metastasis and metastasis of the RLL
  **15**            72              M         Oct 2012                Lung adenocarcinoma                                                                                            IIb         Primary carcinoma (mass) RUL and ML, satellite nodules RLL                                                                                                      Cisplatin/vinorelbine, then carboplatin/pemetrexed                       Yes      RUL+ML lobectomy bilateral metastatic adenocarcinoma                                                                                                            Oct 2017                 No                                                                        RUL+ML lobectomy bilateral metastatic adenocarcinoma

RT: radiotherapy; IP: immune-related pneumonitis; ICI: immune checkpoint inhibitors; LUL: left upper lobe; RUL: right upper lobe; LN: lymph node; LLL: left lower lobe; RLL: right lower lobe; ML: middle lobe; NA: not available.

###### 

Patient characteristics

  **Case number**   **Time of onset of ICI**   **ICI agent (clinical trial or RC)**   **Events between onset of ICI and IP**          **Time of IP onset**   **Time of IP onset after beginning of ICI months**   **IP severity grade according to CTCAE 4.0**   **Symptoms**          **Diagnostic method**           **ICI interruption or discontinuation**   **Steroid treatment**   **IP outcome**
  ----------------- -------------------------- -------------------------------------- ----------------------------------------------- ---------------------- ---------------------------------------------------- ---------------------------------------------- --------------------- ------------------------------- ----------------------------------------- ----------------------- -----------------------------------------------------------
  **1**             April 2015                 P (RC)                                 Concurrent *Pseudomonas aeruginosa* pneumonia   June 2017              26                                                   4                                              Respiratory failure   BAL                             Discontinued June 2017                    Yes                     Death after initial clinical and radiological improvement
  **2**             Aug 2016                   N (clinical trial)                     Cryotherapy of the chest wall metastasis        Oct 2017               13                                                   3                                              Dyspnoea              Response to therapy             Discontinued Sept 2017                    Yes                     Clinical and radiological improvement
  **3**             July 2016                  I+N then N (RC)                        No                                              April 2017             9                                                    1                                              None                  Histology (surgical excision)   No                                        No                      Clinical and radiological improvement
  **4**             Dec 2016                   I+N then N (RC)                        No                                              March 2017             3                                                    3                                              Dyspnoea, cough       BAL                             Discontinued March 2017                   Yes                     Clinical and radiological improvement
  **5**             July 2016                  I+N then N (RC)                        No                                              Dec 2016               5                                                    1                                              None                  BAL                             Discontinued Dec 2016                     No                      Clinical and radiological improvement
  **6**             Nov 2016                   N (RC)                                 No                                              Feb 2017               2                                                    3                                              Dyspnoea              Response to therapy             Discontinued Feb 2017                     Yes                     Clinical and radiological improvement
  **7**             April 2016                 D+T (clinical trial)                   No                                              June 2016              2                                                    3                                              Dyspnoea, cough       BAL                             Discontinued June 2016                    Yes                     Clinical and radiological improvement
  **8**             June 2016                  N (RC)                                 No                                              July 2017              13                                                   1                                              None                  BAL                             Discontinued June 2017                    Yes                     Clinical and radiological improvement
  **9**             May 2015                   I (clinical trial)                     No                                              Sept 2015              4                                                    1                                              None                  BAL and histology               Discontinued June 2017                    Yes                     Clinical and radiological improvement
  **10**            Oct 2015                   N (RC)                                 No                                              July 2016              8                                                    4                                              Dyspnoea              BAL                             Discontinued July 2016                    Yes                     Clinical and radiological improvement
  **11**            Aug 2016                   I+N (RC)                               No                                              Oct 2016               2                                                    1                                              None                  Histology                       Discontinued Oct 2016                     Yes                     Clinical and radiological improvement
  **12**            March 2017                 P (clinical trial)                     No                                              Sept 2017              6                                                    1                                              Dyspnoea, cough       BAL                             No                                        No                      Slowed progression
  **13**            Sept 2016                  N (RC)                                 Unproven superimposed infection of the RUL      Feb 2017               5                                                    3                                              Dyspnoea              BAL                             Discontinued Feb 2017                     Yes                     Clinical and radiological improvement
  **14**            Sept 2010                  I (RC)                                 No                                              Oct 2010               1                                                    3                                              Cough                 BAL                             Discontinued Oct 2010                     Yes                     Clinical and radiological improvement
  **15**            Aug 2016                   N (RC)                                 RT                                              Feb 2018               17                                                   3                                              Dyspnoea              BAL                             Discontinued Jan 2018                     Yes                     Clinical and radiological improvement

ICI: immune checkpoint inhibitors; RC: routine care; IP: immune-related pneumonitis; CTCAE: Common Terminology Criteria for Adverse Events; P: pembrolizumab; N: nivolumab; I: ipilimumab; D: durvalumab; T: tremelimumab; RUL: right upper lobe; RT: radiotherapy; BAL: bronchoalveolar lavage.

10 patients (67%) underwent RT, six of whom did so before ICIs, while three patients received concurrent ICIs and RT (20%), and one (case 1) had RT both before and during ICIs. Seven patients developed imaging features compatible with radiation-induced pneumonitis within 6 months after RT. RT treatments are detailed in [table 3](#TB3){ref-type="table"}.

###### 

Details of thoracic radiotherapy (RT)

  **Case number**   **Type**                                             **Site**                                 **Dose Gy**   **Fractions**   **Radiation pneumonitis**   **Time between RT and immunotherapy months**
  ----------------- ---------------------------------------------------- ---------------------------------------- ------------- --------------- --------------------------- ----------------------------------------------
  **1**             Treatment of lung metastasis                         Pericardium: left inferoposterior wall   40            4               Yes                         4
  **1**             Treatment of lung metastasis                         LLL                                      48            4               Yes                         3
  **1**             Treatment of lung metastasis                         Right hilum                              52            7               Yes                         Concurrent
  **1**             Treatment of lung metastasis                         RLL                                      52            7               Yes                         Concurrent
  **2**             Treatment of primary tumour                          LUL                                      66            33              Yes                         40
  **2**             Stereotactic radiotherapy of synchronous carcinoma   RUL                                      60            8               Yes                         37
  **3**             Palliative                                           Spine D7--D11                            30            10              No                          1
  **4**             Treatment of lung metastasis                         RLL                                      45            9               Yes                         17
  **8**             Treatment of primary tumour                          Mediastinum                              60            30              No                          4
  **9**             Treatment of primary tumour                          RLL                                      45            30              Yes                         2
  **10**            Treatment of primary tumour                          Mediastinum                              60            30              Yes                         12
  **12**            Palliative                                           Scapula                                  25            5               No                          Concurrent
  **13**            Palliative                                           RUL and mediastinum                      39            13              Yes                         10
  **15**            Palliative                                           RUL                                      30            10              Yes                         Concurrent

LLL: left lower lobe; RLL: right lower lobe; LUL: left upper lobe; RUL: right upper lobe.

During the 18 months prior to IP, four patients (27%) had a pulmonary infection (one *Pseudomonas aeruginosa* pneumonia, one rhinovirus bronchiolitis, one *Pneumocystis jiroveci* pneumonia, one community-acquired pneumonia), one (6%) had chemotherapy-induced pneumonia (case 6) and one (6%) underwent cryoablation of a lung metastasis (case 2). Other lung disorders included chronic obstructive pulmonary disease (n=6).

According to CTCAE version 4, the severity of IP was classified as grade 1 in six cases (40%), grade 3 in seven cases (47%) and grade 4 in two cases (13%). In grade 1 patients, IP was initially identified by scheduled imaging for restaging (positron emission tomography/CT in three and CT in three). BAL was performed in 11 patients (74%), whereas the diagnosis of IP was histologically proven in two, including one by transbronchial biopsy and one with a surgical specimen (13%). In two other patients (13%), the severity of the clinical condition did not allow any invasive procedures and diagnosis was made through improvement under immunosuppressive treatment. BAL results are detailed in [table 4](#TB4){ref-type="table"}. A predominantly lymphocytic or mixed pattern was observed in all but one patient with respiratory failure, in whom BAL demonstrated a neutrophilic profile.

###### 

Computed tomography (CT) analysis and comparison with bronchoalveolar lavage (BAL) results

  **Case number**   **Lung regions involved by IP**   **Additional findings**                                                                         **RT**   **Radiation pneumonitis**   **CT pattern**                               **BAL/biopsy pattern**
  ----------------- --------------------------------- ----------------------------------------------------------------------------------------------- -------- --------------------------- -------------------------------------------- -------------------------
  **1**             Diffuse                           Pleural effusion, increasing GGOs over time                                                     Yes      Yes                         DAD and OP                                   Neutrophilic
  **2**             UR, LR, ML, LL                                                                                                                    Yes      Yes                         OP                                           NA
  **3**             UR                                Lung nodule increasing over time                                                                Yes      No                          Nodule                                       Lymphocytic (histology)
  **4**             Diffuse                                                                                                                           Yes      Yes                         OP, cNSIP                                    Mixed
  **5**             Diffuse                                                                                                                           No       NA                          cNSIP                                        Mixed
  **6**             Diffuse                           Pre-existing lobular attenuation, excluding HP                                                  No       NA                          cNSIP and OP                                 NA
  **7**             Diffuse                           Migratory pattern, pleural effusion                                                             No       NA                          Mixed OP and cNSIP ± other unspecified ILD   Lymphocytic
  **8**             UR, ML, LL                        Migratory pattern                                                                               Yes      No                          OP                                           Lymphocytic
  **9**             MR, LR                            Migratory pattern                                                                               Yes      Yes                         OP                                           Mixed
  **10**            Diffuse                                                                                                                           Yes      Yes                         OP                                           Mixed
  **11**            UR, MR, LR, ML, LL                                                                                                                No       NA                          OP, cNSIP                                    NA
  **12**            UR, MR, UL, ML                    Migratory pattern                                                                               Yes      No                          OP                                           Normal
  **13**            Diffuse                                                                                                                           Yes      Yes                         OP                                           Mixed
  **14**            Diffuse                           Perilymphatic micronodularity, peribronchovascular consolidation and mosaic perfusion pattern   No       NA                          LIP, cNSIP, DAD                              Lymphocytic
  **15**            Diffuse                           Migratory pattern and pleural effusion                                                          Yes      No                          OP                                           Mixed

IP: immune-related pneumonitis; RT: radiation therapy; BAL: bronchoalveolar lavage; UR: upper right; LR: lower right; ML: medium left; LL: lower left; MR: medium right; UL: upper left; GGO: ground-glass opacity; HP: hypersensitivity pneumonitis; NA: not available; DAD: diffuse alveolar damage; OP: organising pneumonia; cNSIP: cellular nonspecific interstitial pneumonia; LIP: lymphoid interstitial pneumonia; ILD: interstitial lung disease.

Imaging characteristics are shown in [tables 4](#TB4){ref-type="table"} and [5](#TB5){ref-type="table"}. On the baseline scan, RT-naïve tumoral lesions related to primary lung tumour were seen in four regions and metastasis in four regions ([table 5](#TB5){ref-type="table"}). 13 RT-treated neoplastic lesions -- either primary lung cancer or metastasis -- resulted in 21 irradiated regions on the baseline scan. Imaging findings compatible with radiation-induced pneumonitis occurring within the field of RT and within 6 months after treatment were observed in six cases. These radiation-induced abnormalities were not considered for the specific description of the IP pattern due to potential overlapping features of radiation pneumonitis (RP) and IP.

###### 

Correlation between immune-related pneumonitis (IP) extension and underlying lung conditions

  **Case number**   **Timing**   **Upper left**   **Middle left**   **Lower left**   **Upper right**   **Middle right**   **Lower right**   **IP lesions in RT field**   **Possible triggers and/or other findings**
  ----------------- ------------ ---------------- ----------------- ---------------- ----------------- ------------------ ----------------- ---------------------------- --------------------------------------------------------------------------------------------------
  **1**             Baseline     0                RT                RT               0                 RT                 RT                                             *Pseudomonas aeruginosa* pneumonia and synergistic lymphocyte activation by immunotherapy and RT
  IP                26--50%      76--100%         26--50%           51--75%          51--75%           26--50%            80%                                            
  **2**             Baseline     Lobectomy        M                 0                RT (T)            0                  T                                              Recall effect RT upper right and cryoablation lower left
  IP                Lobectomy    76--100%         76--100%          26--50%          0                 51--75%            90%                                            
  **3**             Baseline     0                0                 0                T                 0                  0                                              No specific trigger but close to T; no correlation with RT
  IP                0            0                0                 1--25%           0                 0                  0%                                             
  **4**             Baseline     0                0                 0                0                 0                  RT (M)                                         Recall effect RT
  IP                26--50%      1--25%           1--25%            26--50%          26--50%           51--75%            60%                                            
  **5**             Baseline     0                0                 0                0                 0                  0                                              Rhinovirus bronchiolitis 2 months before
  IP                26--50%      26--50%          26--50%           26--50%          26--50%           26--50%            NA                                             
  **6**             Baseline     0                0                 T                0                 0                  0                                              Marked in the T side; drug-induced pneumonia 6 months before
  IP                76--100%     76--100%         76--100%          26--50%          26--50%           51--75%            NA                                             
  **7**             Baseline     0                T                 0                0                 0                  0                 NA                           Marked in the T region
  IP                51--75%      76--100%         76--100%          26--50%          26--50%           26--50%                                                           
  **8**             Baseline     0                0                 M                RT (T)            RT                 0                                              Marked in the M region; *Pneumocystis jiroveci* pneumonia 18 months before
  IP                0            1--25%           26--50%           26--50%          0                 0                  25%                                            
  **9**             Baseline     0                0                 0                0                 RT (T)             RT                100%                         Lymphocyte activation by RT
  IP                0            0                0                 0                26--50%           1--25%                                                            
  **10**            Baseline     0                RT (T)            0                0                 RT                 0                                              Recall effect RT
  IP                76--100%     76--100%         1--25%            26--50%          26--50%           1--25%             80%                                            
  **11**            Baseline     0                0                 0                M                 0                  0                                              No specific trigger but close to M
  IP                0            1--25%           1--25%            51--75%          26--50%           26--50%            NA                                             
  **12**            Baseline     0                0                 0                RT (M)            0                  0                                              Synergistic lymphocyte activation by immunotherapy and RT
  IP                1--25%       26--50%          0                 26--50%          26--50%           0                  75%                                            
  **13**            Baseline     RT               0                 0                RT (T)            RT (T)             0                                              Recall effect RT
  IP                26--50%      26--50%          1--25%            51--75%          76--100%          76--100%           100%                                           
  **14**            Baseline     0                0                 0                0                 M                  0                                              None
  IP                76--100%     76--100%         76--100%          51--75%          76--100%          76--100%           NA                                             
  **15**            Baseline     RT               RT                RT               RT (T)            Lobectomy          RT (T)                                         Synergistic lymphocyte activation by immunotherapy and RT
  IP                26--50%      26--50%          51--75%           51--75%          NA                76--100%           80%                                            

In patients who underwent radiation therapy, radiation therapy (RT) is used in the baseline row to identify the lung regions included in the radiation field. The tumour manifestation (primary tumour (T) or metastasis (M)) is added in parenthesis whenever the tumour manifestation was located in that irradiated region. NA: not available.

Two lung regions were missing on the IP scan due to surgery; therefore, 88 regions were evaluated. The IP scan showed IP-related lesions in 72 (81%) out of 88 pulmonary regions, whereas 16 (19%) out of 88 regions were free of IP. The IP-free regions were also free of tumour, metastasis or RT on the baseline scan. Conversely, a significant prevalence of IP-related lesions was found in the regions of primary tumour (n=4), metastasis (n=4) and RT (n=21) (p=0.009), with an odds ratio of 10.8 for IP occurrence in these regions (p=0.024). The analysis of RT cases alone showed also a trend for a higher prevalence of IP in RT regions (95%) compared to RT-naïve regions (5%, p=0.061).

Various imaging patterns, distributions and degrees of lung involvement were observed in the same patient and between patients ([table 4](#TB4){ref-type="table"}). Nine patients (60%) had IP-related abnormalities over all lung fields bilaterally. Regarding the overall pattern of interstitial lung disease, CT findings were consistent with pure OP in 7 patients (47%), combined OP and NSIP in four cases (27%), and combined OP and DAD in one patient (6%; case 1). In two cases, no characteristic features were detected and the pattern was considered undefined (12.5%). A solitary nodule increasing in size over time was seen in one patient and led to surgical resection with pathological proof of IP (6%). Pleural effusion was seen in three patients (20%). A pure OP pattern was found more frequently in patients who underwent RT than those who did not (70% *versus* 0%, p=0.024), whereas NSIP features were identified more frequently in those who did not receive RT (100 *versus* 10%, p=0.002). Two illustrative cases are shown in [figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}.

![Immune-related pneumonitis grade 3 with organising pneumonia computed tomography (CT) pattern developed during nivolumab treatment in an 88-year-old man with non-small cell lung cancer infiltrating the third and fourth right ribs (cT3 cN1 cM0, stage IIIA). a) Radiation therapy field (\*), 39 Gy in 13 fractions of 3 Gy (red: 50 Gy; blue: 5 Gy). b) CT scan performed 2 months after radiation therapy showing radiation-induced pneumonitis (arrows). Abnormalities in the contralateral lung are mainly due to poor inspiration. c) CT scan before starting nivolumab, 6 months after radiotherapy, showing almost complete resolution of the radiation-induced pneumonitis. After 4 months of nivolumab, the patient developed grade 3 dyspnoea. d and e) New alveolar and partly peribronchovascular consolidations (arrows) are visible. f) The consolidations are located within the radiation field, as revealed by the fusion CT--radiation therapy planning image (red: 50 Gy; blue: 5 Gy). However, g--i) some consolidations are also located outside the radiation field in the fusion CT--radiation therapy planning image (i, arrows), especially at the right lower lobe (g) and in a subpleural location on the contralateral side (h, arrow).](00165-2019.01){#F1}

![Immune-related pneumonitis grade 1 with organising pneumonia features developed after two cycles of combined therapy with nivolumab and ipilimumab in a 46-year-old man with metastatic melanoma. a) Lung metastasis (\*) of the right upper lobe on baseline computed tomography (CT) scan. b) The restaging CT performed after the first cycle shows a focal area of ground-glass opacity (arrows) in the vicinity of the lung metastasis (\*). The patient was asymptomatic. c and d) 1 month later, the ground-glass opacity has disappeared but new-onset subpleural and peribronchovascular consolidations (arrows) are seen close to the metastasis. No CT abnormalities are found in the contralateral lung.](00165-2019.02){#F2}

Discussion {#s4}
==========

In the present study, we found that IP triggered by ICIs preferentially locates within the regions of primary cancer, lung metastasis and/or RT fields (p=0.009). Even if IP could involve adjacent or distant areas, including the contralateral lung, the probability that IP abnormalities affected primary tumour, metastasis and/or RT regions was 10.8 times higher than in the others. While no increased risk of IP has been demonstrated so far when using combined RT-ICIs \[[@C2], [@C3], [@C19]\], this study is the first to describe IP abnormalities predominantly within the irradiated areas, as well as within the lung regions involved by the cancer, either the primary tumour or metastasis in RT-naïve patients.

Although the pathogenesis of IP is largely unknown, immune dysregulation likely plays a role, as pathological specimens are typically characterised by lymphocyte infiltration \[[@C20]\]. It can be hypothesised that during immunotherapy, lung homeostasis is altered and an autoimmune reaction is triggered \[[@C21], [@C22]\]. In this setting, it is conceivable that the predominant reaction is seen firstly where the lymphocytes are pooled, such as around tumoral lesions or within the RT field, and it could then diffuse to the surrounding areas and, in some cases, to distant regions. Moreover, in addition to RT, several pulmonary events, including pulmonary infection, cryoablation of a lung metastasis and chemotherapy-induced pneumonia, could have further altered immune homeostasis ([table 5](#TB5){ref-type="table"}). These local conditions could have promoted inflammatory responses and caused a hyperactivation of the immune system leading to irAEs.

Our finding of a preferential location of IP to RT fields is of particular interest. Several trials have raised the interest of administering immunotherapy with other treatments, particularly RT, since their antitumoural effects may be enhanced when combined \[[@C2], [@C6]--[@C9], [@C23]\].

In addition to its antitumoural effects, RT promotes an immune, mainly T-cell-mediated, response known as "*in situ* vaccination", which plays an important role in the outcome of RT \[[@C21], [@C22], [@C24]\]. This immune system activation is not restricted to the RT field but also induces a systemic, tumour-specific immune response outside the RT field due to immunogenic cell death. This phenomenon could be related to the "abscopal effect", a radiation-induced mechanism where reduction of tumour burden is observed not only in the RT field but also outside. The interest of the abscopal effect has been recently underlined by pre-clinical and clinical evidence of tumour shrinking outside the radiation field when RT was used in combination with ICIs \[[@C22], [@C24], [@C25]\]. In case 15, treated by combined RT-ICIs, a significant response of all metastases was observed after the irradiation of the largest lesion, while no tumour reduction was previously observed during immunotherapy alone. Interestingly, a predominant location of IP was seen around all metastases.

Beside the hopeful synergic antitumoural effects of combined ICI-RT, particular attention has been paid to irAEs, including lung toxicities in case of thoracic RT, as it could be hypothesised that these toxicities would be increased by the enhanced pro-inflammatory activities. However, the first clinical data suggest that a safe and tolerable profile is maintained \[[@C2], [@C6], [@C23], [@C26]\]. Nevertheless, it has been recently described that immunotherapy may cause an inflammatory reaction in previously irradiated area as a RP or even years after irradiation, owing to the known "recall effect" \[[@C5], [@C14]--[@C16], [@C27]--[@C29]\]. These biological effects reinforce the interest of combined radiotherapy and immunotherapy, and could partly explain the predominant location of IP abnormalities within RT fields \[[@C2]--[@C4], [@C19]\]. Although in case of previous RT, it may be difficult to strictly attribute observed changes to either IP or RP, our observations in RT-free cases rules out a recall effect alone. Further studies are needed to investigate whether the interval between RT and immunotherapy administration may influence the incidence of pneumonitis within the radiation field. Similarly to RT, cryoablation causes direct neoplastic cell death and stimulates a local immune response so that, when combined with immunotherapy, it may also act by immunogenic cell death \[[@C30]\].

Similarly to previous studies, the detailed evaluation of CT characteristics did not show a specific pattern of IP \[[@C12], [@C13], [@C31]\]. Although OP and NSIP features were frequently observed, a specific pattern could not be defined in some cases, as previously reported by N[aidoo]{.smallcaps} *et al.* \[[@C12]\]. In patient 1, an increasing ground-glass opacification pattern on a background of subpleural consolidations was detected on consecutive scans, suggesting an OP evolving to DAD, which matched the worsening of the clinical condition towards respiratory failure. Such an "evolving pattern" has rarely been reported \[[@C12]\]. Interestingly, in the present study, a pure OP pattern was more frequently found in patients who underwent RT (p=0.024), whereas NSIP features were more commonly seen in patients who did not have RT (p=0.002).

The present study has several limitations, including its retrospective design, the small sample size, and variations in tumour histology and treatments. Additional studies with larger sample size are required to confirm our results. A correlation between ICI efficacy on the tumoural burden and occurrence of IP was not analysed, and also requires further studies. One could argue that confusion may have occurred between radiation-induced pneumonia and IP. However, among the 10 cases who underwent RT, eight had opacities attributable to IP outside the radiation field, making the diagnosis of pure RP unlikely. In the two remaining cases (9 and 13), 100% of opacities attributed to IP were located in the radiation field ([table 5](#TB5){ref-type="table"}) but in both of them, IP occurred ≥6 months after RT, again making the diagnosis of pure RP unlikely. Additionally, similar morphological abnormalities were also observed in RT-naïve patients, especially in lung areas involved by tumour (either primary tumour or metastasis), which also argues against pure RP. We therefore believe that no confusion occurred between RP and IP in the present study. Nevertheless, further studies are required to examine the relationships between these two events, as well as the possible triggering role of other events such as lung infections, which might also alter lung homeostasis and play a role in IP development.

In conclusion, the present study showed a predominance of IP features in the site of cancer and/or RT areas. Although the mechanisms remain unclear, this finding could be related to a higher pool of lymphocytes in these areas during ICI treatment. This immune reaction could then extend to adjacent regions as well as distant ones by cascade activation. A comprehensive understanding of IP pathogenesis, causes and imaging features may allow earlier detection, with a relevant impact on patient care. In patients receiving ICIs, the detection of new-onset radiological abnormalities within either the region of neoplastic lesion or the RT field should alert the clinician to consider IP in the differential diagnosis, allowing prompt and correct management.
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